Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
This study is recruiting at 11 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Giant Cell Tumor of Bone
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- St. Louis University
- Last updated on ClinicalTrials.gov
- April 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California - Los Angeles · Los Angeles, CA
Indiana · 1
- Indiana University · Indianapolis, IN
Iowa · 1
- University of Iowa · Iowa City, IA
Maryland · 1
- Johns Hopkins University Hospital · Baltimore, MD
Massachusetts · 3
- Beth Israel Deaconess Medical Center · Boston, MA
- Boston Children's Hospital · Boston, MA
- Massachusetts General Hospital · Boston, MA
Missouri · 1
- Saint Louis University · St Louis, MO
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Oklahoma · 1
- University of Oklahoma · Oklahoma City, OK
Pennsylvania · 1
- Allegheny-Singer Research Institute · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.